Albireo Pharma, Inc. (ALBO) Stock

About Albireo Pharma, Inc.

Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.

Albireo Pharma, Inc. is headquartered in US.

Albireo Pharma, Inc. (ALBO) stock trades at $44.15 with a market capitalization of $915.89M. The stock is valued at a price-to-earnings (P/E) ratio of -5.61, price-to-book of 4.83, price-to-sales of 22.57. Over the past 52 weeks the stock has ranged between $16.02 and $45.23, and currently trades 2.4% below its 52-week high.

On profitability, Albireo Pharma, Inc. generates a return on equity (ROE) of -84.83%, return on capital employed of -48.10%, an operating margin of -304.31%, a net profit margin of -372.97%.

Official website: www.albireopharma.com